| abstract |
The present invention discovers that a series of small-molecule immune stimulants are coupled with targeted drugs to form new targeted compound drugs with immune activation function, which is conducive to improving the immune activation effect of targeted drugs and anti-tumor and other diseases in vitro and in vivo. effect, endowing the targeted drug with dual functions (dual-functional targeted drug), this improved effect is caused by the two functions of immune anti-tumor factors (such as IFN-γ) and inhibition of pathogenic targeting sites. Functional synergy is produced, a new type of high-efficiency targeted drug that combines two functions into one. |